-
公开(公告)号：US06649600B1
公开(公告)日：2003-11-18
申请号：US09711543
申请日：2000-11-13
申请人： William F. Kiesman , Carol L. Ensinger , Russell C. Petter , James E. Dowling , Gnanasambandam Kumaravel , He Xi Chang , Ko Chung Lin
发明人： William F. Kiesman , Carol L. Ensinger , Russell C. Petter , James E. Dowling , Gnanasambandam Kumaravel , He Xi Chang , Ko Chung Lin
IPC分类号： C07D51900
CPC分类号： C07D473/06 , C07D473/22 , C07F9/65616
摘要： The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be usefull in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula I: wherein: R3 is an optionally substituted bicyclic, tricylic, or pentacyclic group selected from: and wherein R1, R2, R6, X1, X2, and Z are as described in the specification.
摘要翻译： 本发明基于以下发现：式I化合物是意想不到的高度有效和选择性的腺苷A1受体抑制剂。 腺苷A1拮抗剂可用于预防和/或治疗许多疾病，包括心脏和循环障碍，中枢神经系统的退行性疾病，呼吸系统疾病以及利尿剂治疗适用的许多疾病。在一个实施方案中，本发明 具有式I化合物：其中：R 3是选自以下的任选取代的二环，三环或五环：其中R 1，R 2，R 6，X 1，X 2和Z如说明书中所述。
-
公开(公告)号：US06605600B1
公开(公告)日：2003-08-12
申请号：US09711554
申请日：2000-11-13
IPC分类号： C07D47306
CPC分类号： C07D473/02 , C07D473/04 , C07D473/06
摘要： The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula I: R3 is an optionally substituted group selected from: and wherein X1, X2, Z, R1, R2, and R6 are as described in the specification.
摘要翻译： 本发明基于以下发现：式I化合物是意想不到的高度有效和选择性的腺苷A1受体抑制剂。 腺苷A1拮抗剂可用于预防和/或治疗许多疾病，包括心脏和循环障碍，中枢神经系统的退行性疾病，呼吸系统疾病以及许多适用于利尿剂治疗的疾病。在一个实施方案中，本发明 具有式I化合物：R 3是选自以下的任选取代的基团：其中X 1，X 2，Z，R 1，R 2和R 6如说明书中所述。
-
3.发明申请公开(公告)号：US20090221821A1
公开(公告)日：2009-09-03
申请号：US12368469
申请日：2009-02-10
IPC分类号： C07D473/04
CPC分类号： C07D473/06 , C07D473/22 , C07F9/65616
摘要： The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.In one embodiment, the invention features a compound of formula I:
摘要翻译： 本发明基于以下发现：式I化合物是意想不到的高度有效和选择性的腺苷A1受体抑制剂。 腺苷A1拮抗剂可用于预防和/或治疗许多疾病，包括心脏和循环系统疾病，中枢神经系统的退行性疾病，呼吸系统疾病以及适合利尿治疗的许多疾病。 在一个实施方案中，本发明的特征在于式I的化合物：
-
公开(公告)号：US07579354B2
公开(公告)日：2009-08-25
申请号：US11484805
申请日：2006-07-10
申请人： William F. Kiesman , Carol L. Ensinger , Russell C. Petter , James E. Dowling , Gnanasambandam Kumaravel , He Xi Chang , Ko Chung Lin
发明人： William F. Kiesman , Carol L. Ensinger , Russell C. Petter , James E. Dowling , Gnanasambandam Kumaravel , He Xi Chang , Ko Chung Lin
IPC分类号： A61P9/08 , A61P9/10 , A61P13/12 , A61P9/04 , A61K31/522 , C07D519/00 , C07D473/06 , A61P11/06 , A61P3/10
CPC分类号： C07D473/06 , C07D473/22 , C07F9/65616
摘要： The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.In one embodiment, the invention features a compound of formula I:
摘要翻译： 本发明基于以下发现：式I化合物是意想不到的高度有效和选择性的腺苷A1受体抑制剂。 腺苷A1拮抗剂可用于预防和/或治疗许多疾病，包括心脏和循环系统疾病，中枢神经系统的退行性疾病，呼吸系统疾病以及适合利尿治疗的许多疾病。 在一个实施方案中，本发明的特征在于式I的化合物：
-
公开(公告)号：US07674791B2
公开(公告)日：2010-03-09
申请号：US10552305
申请日：2004-04-09
申请人： James E. Dowling , Gang Yao , Hexi Chang , Hairuo Peng , Jeffrey Vessels , Russell C. Petter , Gnanasambandam Kumaravel
发明人： James E. Dowling , Gang Yao , Hexi Chang , Hairuo Peng , Jeffrey Vessels , Russell C. Petter , Gnanasambandam Kumaravel
IPC分类号： A61K31/4985
CPC分类号： C07D241/20 , C07D487/04
摘要： The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula I (See formula on paper copy)
摘要翻译： 本发明基于以下发现：式（I）化合物对A2a腺苷受体具有意想不到的高亲和力，并且可用作其拮抗剂，用于预防和/或治疗包括帕金森病在内的许多疾病。 在一个实施方案中，本发明的特征在于式I的化合物（参见纸上的公式）
-
公开(公告)号：US20230219949A1
公开(公告)日：2023-07-13
申请号：US17969043
申请日：2022-10-19
申请人： Bryce A. Harrison , James E. Dowling , Aleksey I. Gerasyuto , Matthew M. Bursavich , Dawn M. Troast , Blaise S. Lippa , Bruce N. Rogers , Cheng Zhong , Qi Qiao , Fu-Yang Lin , Brian Sosa , Andrea Bortolato , Mats A. Svensson , Eugene Hickey , Tyler Day , Byungchan Kim , Kyle D. Konze
发明人： Bryce A. Harrison , James E. Dowling , Aleksey I. Gerasyuto , Matthew M. Bursavich , Dawn M. Troast , Blaise S. Lippa , Bruce N. Rogers , Cheng Zhong , Qi Qiao , Fu-Yang Lin , Brian Sosa , Andrea Bortolato , Mats A. Svensson , Eugene Hickey , Tyler Day , Byungchan Kim , Kyle D. Konze
IPC分类号： C07D471/04 , C07D519/00 , A61K9/00
CPC分类号： C07D471/04 , C07D519/00 , A61K9/0053
摘要： Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.028 秒)
